

REFERENCES

- Augusto, T. V., Correia-da-Silva, G., Rodrigues, C. M. P., Teixeira, N., & Amaral, C. (2018). Acquired resistance to aromatase inhibitors: where we stand! *Endocrine-Related Cancer*, 25(5), R283–R301. <https://doi.org/10.1530/ERC-17-0425>
- Banik, K., Ranaware, A. M., Deshpande, V., Nalawade, S. P., Padmavathi, G., Bordoloi, D., Sailo, B. L., Shanmugam, M. K., Fan, L., Arfuso, F., Sethi, G., & Kunnumakkara, A. B. (2019). Honokiol for cancer therapeutics: A traditional medicine that can modulate multiple oncogenic targets. *Pharmacological Research*, 144, 192–209. <https://doi.org/10.1016/J.PHRS.2019.04.004>
- Boekhout, A. H., Beijnen, J. H., & Schellens, J. H. M. (2011). Trastuzumab. *The Oncologist*, 16(6), 800–810. <https://doi.org/10.1634/THEONCOLOGIST.2010-0035>
- Bonam, S. R., Wu, Y. S., Tunki, L., Chellian, R., Halmuthur, M. S. K., Muller, S., & Pandey, V. (2018). What Has Come out from Phytomedicines and Herbal Edibles for the Treatment of Cancer? *ChemMedChem*, 13(18), 1854–1872. <https://doi.org/10.1002/CMDC.201800343>
- Buchan, N. S., Rajpal, D. K., Webster, Y., Alatorre, C., Gudivada, R. C., Zheng, C., Sanseau, P., & Koehler, J. (2011). The role of translational bioinformatics in drug discovery. *Drug Discovery Today*, 16(9–10), 426–434. <https://doi.org/10.1016/J.DRUDIS.2011.03.002>
- Carraway, K. L., & Idris, N. (2001). Regulation of sialomucin complex/Muc4 in the female rat reproductive tract. *Biochemical Society Transactions*, 29(2), 162–166. <https://doi.org/10.1042/BST0290162>
- Chin, C. H., Chen, S. H., Wu, H. H., Ho, C. W., Ko, M. T., & Lin, C. Y. (2014). cytoHubba: Identifying hub objects and sub-networks from complex interactome. *BMC Systems Biology*, 8(4), 1–7. <https://doi.org/10.1186/1752-0509-8-S4-S11/TABLES/4>
- Chuaychai, A., & Sriplung, H. (2022). A rapid rise in hormone receptor-positive and HER2-positive breast cancer subtypes in Southern Thai women: A population-based study in Songkhla. *PLOS ONE*, 17(3), e0265417. <https://doi.org/10.1371/JOURNAL.PONE.0265417>
- Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., & Slamon, D. J. (1999). Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, 17(9), 2639–2648. <https://doi.org/10.1200/JCO.1999.17.9.2639>
- Cronin, K. A., Harlan, L. C., Dodd, K. W., Abrams, J. S., & Ballard-Barbash, R. (2010). Population-based Estimate of the Prevalence of HER-2 Positive Breast Cancer Tumors for Early Stage Patients in the US. *Http://Dx.Doi.Org/10.3109/07357907.2010.496759*, 28(9), 963–968. <https://doi.org/10.3109/07357907.2010.496759>

- Felcher, C. M., Bogni, E. S., & Kordon, E. C. (2022). IL-6 Cytokine Family: A Putative Target for Breast Cancer Prevention and Treatment. *International Journal of Molecular Sciences*, 23(3), 1809. <https://doi.org/10.3390/ijms23031809>
- Fizman, G. L., & Jasnits, M. A. (2011). Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer. *International Journal of Breast Cancer*, 2011, 1–11. <https://doi.org/10.4061/2011/352182>
- Gajria, D., & Chandarlapaty, S. (2014). HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. *https://doi.org/10.1586/Era.10.226*, 11(2), 263–275. <https://doi.org/10.1586/ERA.10.226>
- Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., Cerami, E., Sander, C., & Schultz, N. (2013). Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Science Signaling*, 6(269). https://doi.org/10.1126/SCISIGNAL.2004088/SUPPL_FILE/2004088_TABLES2.XLS
- Gfeller, D., Grosdidier, A., Wirth, M., Daina, A., Michielin, O., & Zoete, V. (2014). SwissTargetPrediction: a web server for target prediction of bioactive small molecules. *Nucleic Acids Research*, 42. <https://doi.org/10.1093/nar/gku293>
- Gilson, M. K., Liu, T., Baitaluk, M., Nicola, G., Hwang, L., & Chong, J. (2015). BindingDB in 2015: A public database for medicinal chemistry, computational chemistry and systems pharmacology. *Nucleic Acids Research*, 44, 1045–1053. <https://doi.org/10.1093/nar/gkv1072>
- Gu, Y., Gao, H., Zhang, H., John, A., Zhu, X., Shivaram, S., Yu, J., Weinshilboum, R. M., & Wang, L. (2022). TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer. *Oncogene*, 41(35), 4119–4129. <https://doi.org/10.1038/s41388-022-02415-6>
- Han, H., Lee, S., & Lee, I. (2019). NGSEA: network-based gene set enrichment analysis for interpreting gene expression phenotypes with functional gene sets. *BioRxiv*, 636498. <https://doi.org/10.1101/636498>
- Heberle, H., Meirelles, V. G., da Silva, F. R., Telles, G. P., & Minghim, R. (2015). InteractiVenn: A web-based tool for the analysis of sets through Venn diagrams. *BMC Bioinformatics*, 16(1), 1–7. <https://doi.org/10.1186/S12859-015-0611-3/FIGURES/4>
- Hermawan, A., Ikawati, M., Jenie, R. I., Khumaira, A., Putri, H., Nurhayati, I. P., Angraini, S. M., & Muflikhasari, H. A. (2021). Identification of potential therapeutic target of naringenin in breast cancer stem cells inhibition by bioinformatics and in vitro studies. *Saudi Pharmaceutical Journal*, 29(1), 12–26. <https://doi.org/10.1016/j.jsps.2020.12.002>
- Hermawan, A., Putri, H., Hanif, N., Fatimah, N., & Prasetyo, H. H. (2022). Identification of potential target genes of honokiol in overcoming breast cancer resistance to tamoxifen. *Frontiers in Oncology*, 12. <https://doi.org/10.3389/fonc.2022.1019025>
- Hermawan, A., Wagner, E., & Roidl, A. (2016). Consecutive salinomycin treatment reduces doxorubicin resistance of breast tumor cells by diminishing drug efflux pump expression and activity. *Oncology Reports*, 35(3), 1732–1740. <https://doi.org/10.3892/or.2015.4509>

- Hosseinzadeh, A., Merikhian, P., Naseri, N., Eisavand, M. R., & Farahmand, L. (2022). MUC1 is a potential target to overcome trastuzumab resistance in breast cancer therapy. *Cancer Cell International*, 22(1), 1–14. <https://doi.org/10.1186/S12935-022-02523-Z/TABLES/1>
- Hudis, C. A. (2007). Trastuzumab — Mechanism of Action and Use in Clinical Practice. *Https://Doi.Org/10.1056/NEJMra043186*, 357(1), 39–51. <https://doi.org/10.1056/NEJMRA043186>
- Jiang, L., Ren, L., Chen, H., Pan, J., Zhang, Z., Kuang, X., Chen, X., Bao, W., Lin, C., Zhou, Z., Huang, D., Yang, J., Huang, H., Wang, L., Hou, N., & Song, L. (2020). NCAPG confers trastuzumab resistance via activating SRC/STAT3 signaling pathway in HER2-positive breast cancer. *Cell Death & Disease*, 11(7), 547. <https://doi.org/10.1038/s41419-020-02753-x>
- Jimenez, C., Jones, D. R., Rodríguez-Viciana, P., Gonzalez-García, A., Leonardo, E., Wennström, S., Von Kobbe, C., Toran, J. L., R.-Borlado, L., Calvo, V., Copin, S. G., Albar, J. P., Gaspar, M. L., Diez, E., Marcos, M. A. R., Downward, J., Martinez-A, C., Mérida, I., & Carrera, A. C. (1998). Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3-kinase. *The EMBO Journal*, 17(3), 743–753. <https://doi.org/10.1093/EMBOJ/17.3.743>
- Kataoka, Y., Mukohara, T., Shimada, H., Saijo, N., Hirai, M., & Minami, H. (2010). Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. *Annals of Oncology*, 21(2), 255–262. <https://doi.org/10.1093/annonc/mdp304>
- Kim, S., Thiessen, P. A., Bolton, E. E., Chen, J., Fu, G., Gindulyte, A., Han, L., He, J., He, S., Shoemaker, B. A., Wang, J., Yu, B., Zhang, J., & Bryant, S. H. (2016). PubChem Substance and Compound databases. *Nucleic Acids Research*, 44(D1), D1202–D1213. <https://doi.org/10.1093/NAR/GKV951>
- Korkaya, H., Kim, G., Davis, A., Malik, F., Henry, N. L., Ithimakin, S., Quraishi, A. A., Tawakkol, N., D’Angelo, R., Paulson, A. K., Chung, S., Luther, T., Paholak, H. J., Liu, S., Hassan, K. A., Zen, Q., Clouthier, S. G., & Wicha, M. S. (2012). Activation of an IL6 Inflammatory Loop Mediates Trastuzumab Resistance in HER2+ Breast Cancer by Expanding the Cancer Stem Cell Population. *Molecular Cell*, 47(4), 570–584. <https://doi.org/10.1016/j.molcel.2012.06.014>
- Kumar, P., Nagarajan, A., & Uchil, P. D. (2018). Analysis of Cell Viability by the MTT Assay. *Cold Spring Harbor Protocols*, 2018(6), pdb.prot095505. <https://doi.org/10.1101/pdb.prot095505>
- Liao, Y., Wang, J., Jaehnig, E. J., Shi, Z., & Zhang, B. (2019). WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs. *Nucleic Acids Research*, 47(W1), W199–W205. <https://doi.org/10.1093/NAR/GKZ401>
- Liu, H., Zang, C., Emde, A., Planas-Silva, M. D., Rosche, M., Kühnl, A., Schulz, C. O., Elstner, E., Possinger, K., & Eucker, J. (2008). Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer. *European Journal of Pharmacology*, 591(1–3), 43–51. <https://doi.org/10.1016/J.EJPHAR.2008.06.026>
- Liu, J., Li, X., Yang, S., Mou, J., & Lu, H. (2020). Whole exome sequencing and transcriptome-wide profiling identify potentially subtype-relevant genes of

- nasopharyngeal carcinoma. *Pathology - Research and Practice*, 216(12), 153244. <https://doi.org/10.1016/J.PRP.2020.153244>
- Lu, Q., Wang, L., Zhang, Y., Yu, X., Wang, C., Wang, H., Yang, Y., Chong, X., Xia, T., Meng, Y., Wang, Y., Lu, C., Zhou, L., & Li, B. (2016). An anti-ErbB2 fully human antibody circumvents trastuzumab resistance. *Oncotarget*, 7(41), 67129–67141. <https://doi.org/10.18632/oncotarget.11562>
- Maadi, H., Soheilifar, M. H., Choi, W.-S., Moshtaghian, A., & Wang, Z. (2021). Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma. *Cancers*, 13(14), 3540. <https://doi.org/10.3390/cancers13143540>
- Maciej Serda, Becker, F. G., Cleary, M., Team, R. M., Holtermann, H., The, D., Agenda, N., Science, P., Sk, S. K., Hinnebusch, R., Hinnebusch A, R., Rabinovich, I., Olmert, Y., Uld, D. Q. G. L. Q., Ri, W. K. H. U., Lq, V., Frxqwu, W. K. H., Zklfk, E., Edvhg, L. V, ... (2019). فاطمی, ح. Encyclopedia of bioinformatics and computational biology. *Uniwersytet Śląski*, 7(1), 343–354. <https://doi.org/10.2/JQUERY.MIN.JS>
- Martínez-Sáez, O., & Prat, A. (2021). Current and Future Management of HER2-Positive Metastatic Breast Cancer. *JCO Oncology Practice*, 17(10), 594–604. <https://doi.org/10.1200/op.21.00172>
- Matkar, S., Sharma, P., Gao, S., Gurung, B., Katona, B. W., Liao, J., Muhammad, A. B., Kong, X.-C., Wang, L., Jin, G., Dang, C. V., & Hua, X. (2015). An Epigenetic Pathway Regulates Sensitivity of Breast Cancer Cells to HER2 Inhibition via FOXO/c-Myc Axis. *Cancer Cell*, 28(4), 472–485. <https://doi.org/10.1016/j.ccell.2015.09.005>
- Mcdermott, M. S. J., Canonici, A., Ivers, L., Browne, B. C., Madden, S. F., O'brien, N. A., Crown, J., & O'Donovan, N. (2017). Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells. *International Journal of Oncology*, 50(6), 2221–2228. <https://doi.org/10.3892/ijo.2017.3976>
- Ménard, S., Fortis, S., Castiglioni, F., Agresti, R., & Balsari, A. (2001). HER2 as a Prognostic Factor in Breast Cancer. *Oncology*, 61(Suppl. 2), 67–72. <https://doi.org/10.1159/000055404>
- Miricescu, D., Totan, A., Stanescu-Spinu, I. I., Badoiu, S. C., Stefani, C., & Greabu, M. (2020). PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects. *International Journal of Molecular Sciences* 2021, Vol. 22, Page 173, 22(1), 173. <https://doi.org/10.3390/IJMS22010173>
- Molina, M. A., Saez, R., Baselga, J., Clinton, G. M., Ramsey, E. E., Garcia-Barchino, M.-J., Rojo, F., Evans, A. J., Albanell, J., Keenan, E. J., Lluch, A., & Garcia-Conde, J. (2002). NH2-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. *Clinical Cancer Research*, 8(2), 347–353.
- Nagalingam, A., Arbiser, J. L., Bonner, M. Y., Saxena, N. K., & Sharma, D. (2012). Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis. *Breast Cancer Research*, 14(1), 1–16. <https://doi.org/10.1186/BCR3128/FIGURES/6>
- Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., Hortobagyi, G. N., Hung, M.-C., & Yu, D. (2004). PTEN activation contributes to tumor inhibition by trastuzumab,

- and loss of PTEN predicts trastuzumab resistance in patients. *Cancer Cell*, 6(2), 117–127. <https://doi.org/10.1016/j.ccr.2004.06.022>
- Oliveras-Ferraro, C., Vazquez-Martin, A., Martin-Castillo, B., Cufí, S., Barco, S. Del, Lopez-Bonet, E., Brunet, J., & Menendez, J. A. (2010). Dynamic emergence of the mesenchymal CD44posCD24neg/low phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin). *Biochemical and Biophysical Research Communications*, 397(1), 27–33. <https://doi.org/10.1016/J.BBRC.2010.05.041>
- Pandolfi, P. P. (2004). Breast Cancer — Loss of PTEN Predicts Resistance to Treatment. *New England Journal of Medicine*, 351(22), 2337–2338. <https://doi.org/10.1056/NEJMCIBR043143>
- Park, E.-J., Min, H.-Y., Chung, H.-J., Hong, J.-Y., Kang, Y.-J., Hung, T. M., Youn, U. J., Kim, Y. S., Bae, K., Kang, S. S., & Lee, S. K. (2009). Down-regulation of c-Src/EGFR-mediated signaling activation is involved in the honokiol-induced cell cycle arrest and apoptosis in MDA-MB-231 human breast cancer cells. *Cancer Letters*, 277(2), 133–140. <https://doi.org/10.1016/j.canlet.2008.11.029>
- Piñero, J., Queralt-Rosinach, N., Bravo, À., Deu-Pons, J., Bauer-Mehren, A., Baron, M., Sanz, F., & Furlong, L. I. (2015). DisGeNET: a discovery platform for the dynamical exploration of human diseases and their genes. *Database*, 2015. <https://doi.org/10.1093/DATABASE/BAV028>
- Pulivendala, G., Bale, S., & Godugu, C. (2020). Honokiol: A polyphenol neolignan ameliorates pulmonary fibrosis by inhibiting TGF-β/Smad signaling, matrix proteins and IL-6/CD44/STAT3 axis both in vitro and in vivo. *Toxicology and Applied Pharmacology*, 391, 114913. <https://doi.org/10.1016/j.taap.2020.114913>
- Rauf, A., Olatunde, A., Imran, M., Alhumaydhi, F. A., Aljohani, A. S. M., Khan, S. A., Uddin, M. S., Mitra, S., Emran, T. Bin, Khayrullin, M., Rebezov, M., Kamal, M. A., & Shariati, M. A. (2021). Honokiol: A review of its pharmacological potential and therapeutic insights. *Phytomedicine*, 90, 153647. <https://doi.org/10.1016/J.PHYMED.2021.153647>
- Rauf, A., Patel, S., Imran, M., AneelaMaalik, Arshad, M. U., Saeed, F., Mabkhot, Y. N., Al-Showiman, S. S., Ahmad, N., & Elsharkawy, E. (2018). Honokiol: An anticancer lignan. *Biomedicine & Pharmacotherapy*, 107, 555–562. <https://doi.org/10.1016/J.BIOPHA.2018.08.054>
- Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., Swain, S. M., Pisansky, T. M., Fehrenbacher, L., Kutteh, L. A., Vogel, V. G., Visscher, D. W., Yothers, G., Jenkins, R. B., Brown, A. M., ... Wolmark, N. (2005). Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer. *New England Journal of Medicine*, 353(16), 1673–1684. https://doi.org/10.1056/NEJMOA052122/SUPPL_FILE/NEJM_ROMOND_1673SA1.PDF
- Sharma, G. N., Dave, R., Sanadya, J., Sharma, P., & Sharma, K. K. (2010). Various types and management of breast cancer: An overview. *Journal of Advanced Pharmaceutical Technology & Research*, 1(2), 109. <https://www.japtr.org/article.asp?issn=2231-4040;year=2010;volume=1;issue=2;spage=109;epage=126;aulast=Sharma>

- Skolastika, S., Hanif, N., Ikawati, M., & Hermawan, A. (2022). Comprehensive Computational Analysis of Honokiol Targets for Cell Cycle Inhibition and Immunotherapy in Metastatic Breast Cancer Stem Cells. *Evidence-Based Complementary and Alternative Medicine*, 2022, 1–18. <https://doi.org/10.1155/2022/4172531>
- Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer Journal for Clinicians*, 71(3), 209–249. <https://doi.org/10.3322/CAAC.21660>
- Szklarczyk, D., Franceschini, A., Wyder, S., Forslund, K., Heller, D., Huerta-Cepas, J., Simonovic, M., Roth, A., Santos, A., Tsafou, K. P., Kuhn, M., Bork, P., Jensen, L. J., & Von Mering, C. (2015). STRING v10: protein–protein interaction networks, integrated over the tree of life. *Nucleic Acids Research*, 43(D1), D447–D452. <https://doi.org/10.1093/NAR/GKU1003>
- Tabassum, S., Abbasi, R., Ahmad, N., & Farooqi, A. A. (2019). *Targeting of JAK-STAT Signaling in Breast Cancer: Therapeutic Strategies to Overcome Drug Resistance* (pp. 271–281). https://doi.org/10.1007/978-3-030-20301-6_14
- Thulasiraman, P., & Johnson, A. B. (2016). Regulation of Mucin 1 and multidrug resistance protein 1 by honokiol enhances the efficacy of doxorubicin-mediated growth suppression in mammary carcinoma cells. *International Journal of Oncology*, 49(2), 479–486. <https://doi.org/10.3892/IJO.2016.3534/HTML>
- Tian, W., Deng, Y., Li, L., He, H., Sun, J., & Xu, D. (2013). Honokiol synergizes chemotherapy drugs in multidrug resistant breast cancer cells via enhanced apoptosis and additional programmed necrotic death. *International Journal of Oncology*, 42(2), 721–732. <https://doi.org/10.3892/IJO.2012.1739/HTML>
- Vivekanandhan, S., & Knutson, K. L. (2022). Resistance to Trastuzumab. *Cancers*, 14(20), 5115. <https://doi.org/10.3390/cancers14205115>
- Wang, Z., Liang, L., Yin, Z., & Lin, J. (2016). Improving chemical similarity ensemble approach in target prediction. *Journal of Cheminformatics*, 8(1), 1–10. <https://doi.org/10.1186/S13321-016-0130-X/TABLES/5>
- Wishart, D. S. (2008). Bioinformatics in Drug Development and Assessment. [Http://Dx.Doi.Org/10.1081/DMR-55225](http://Dx.Doi.Org/10.1081/DMR-55225), 37(2), 279–310. <https://doi.org/10.1081/DMR-55225>
- Wolf, I., O’Kelly, J., Wakimoto, N., Nguyen, A., Amblard, F., Karlan, B. Y., Arbiser, J. L., & Koeffler, H. P. (2007). Honokiol, a natural biphenyl, inhibits in vitro and in vivo growth of breast cancer through induction of apoptosis and cell cycle arrest. *International Journal of Oncology*, 30(6), 1529–1537. <https://doi.org/10.3892/IJO.30.6.1529/HTML>
- Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P., Hanna, W., Jenkins, R. B., Mangu, P. B., Paik, S., Perez, E. A., Press, M. F., Spears, P. A., Vance, G. H., Viale, G., & Hayes, D. F. (2014). Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. *Archives of*

- Pathology & Laboratory Medicine*, 138(2), 241.
<https://doi.org/10.5858/ARPA.2013-0953-SA>
- Xie, L., Jiang, F., Zhang, X., Alitongbieke, G., Shi, X., Meng, M., Xu, Y., Ren, A., Wang, J., Cai, L., Zhou, Y., Xu, Y., Su, Y., Liu, J., Zeng, Z., Wang, G., Zhou, H., Chen, Q. C., & Zhang, X. (2016). Honokiol sensitizes breast cancer cells to TNF- α induction of apoptosis by inhibiting Nur77 expression. *British Journal of Pharmacology*, 173(2), 344–356.
<https://doi.org/10.1111/bph.13375>
- Xiong, L., Ding, L., Ning, H., Wu, C., Fu, K., Wang, Y., Zhang, Y., Liu, Y., & Zhou, L. (2016). CD147 knockdown improves the antitumor efficacy of trastuzumab in HER2-positive breast cancer cells. *Oncotarget*, 7(36), 57737.
<https://doi.org/10.18632/ONCOTARGET.10252>
- Yao, Z. J., Dong, J., Che, Y. J., Zhu, M. F., Wen, M., Wang, N. N., Wang, S., Lu, A. P., & Cao, D. S. (2016). TargetNet: a web service for predicting potential drug–target interaction profiling via multi-target SAR models. *Journal of Computer-Aided Molecular Design*, 30(5), 413–424.
<https://doi.org/10.1007/S10822-016-9915-2/FIGURES/7>
- Zekri, J., Saadeddin, A., & Alharbi, H. (2021). Frequency and clinical characteristics of HER2 over-expressed breast cancer in Saudi Arabia: a retrospective study. *BMC Women's Health*, 21(1), 1–10.
<https://doi.org/10.1186/S12905-020-01159-3/TABLES/4>